The ILBOW

Startup **TCRA** wishes to be acquired in an **ILBOW**, *Infinite Leverage Buy Out Without debt*, by a group of investors specially selected by TCRA.

TCRA will invite **seven specific large companies**, *Siemens, Roche, Danaher, Abbott, Morgan Stanley, Blackstone and Andreesen Horowitz*, to acquire TCRA in an ILBOW. These companies, **the Big 7**, have been chosen due to their absolute ability to create maximum **gain of value** for TCRA, making TCRA shares worth $**300 billion** in the very short term.

The underlying driving force for this ILBOW is that it will completely resolve a health crisis in the Global South: Rh Disease of the Fetus and Newborn (HDFN) causing the deaths of **160,000** babies and having **100,000** children starting life brain damaged needlessly for lack of funding.

These specific **B7** companies are being invited to do the ILBOW of TCRA because they they are the **top companies in the world**, with **the unique ability** to boost the net asset value, NAV, of the future TCRA royalty cash flow over 20 years to **$300 billion**. Their stature makes the success of the TCRA business plan almost certain. And they will make more money from this deal than any other deal ever, more than plenty to interest even these big **B7** companies. The capital structure of TCRA post-ILBOW: **Big 7 - 38%,** Original investors - **12%**, Philanthropy - **50%**.

For a typical, successful Leveraged Buyout (LBO), private equity firms generally target a **2.0x to 3.0x** cash-on-cash return (Money on Invested Capital or MOIC) over a holding period of **3 to 7 years**. [1,2] **TCRA is an amazing, accelerated LBO opportunity**. The ILBOW of TCRA will return **$300 billion** in **one day** on **zero** invested capital. Thereby, the TCRA ILBOW will be the **Top LBO Performer in History** replacing the Blackstone (Hilton Hotels) LBO. Acquired for **$26 billion**, Hilton returned over **$12 billion** in profit in six years. By comparison, TCRA will be acquired for **zero**, returning **$300 billion** in **one day**.

The basis for this **amazing LBO** is that clinical labs worldwide will earn **a sure $8 trillion** over the next 20 years from lab tests run on automated analyzers. Current clinical labs are still only **50%** automated. Progression to full dark lab automation is inevitable. The **Big4** clinical lab automation oligopoly, *Siemens, Roche, Danaher, Abbott,* dominate clinical lab automation as is. **Big4 will** see to it that future clinical analyzers use TCRA intellectual property. With one action **that they take themselves,** announcing intent to adopt DLA, they can create a gain of value for TCRA of **$300 billion** on the day they announce. Then, **Big 4** will collect **~$1 trillion** in royalties over 20 years for TCRA shareholders, **~$280 billion** in royalties for themselves. **Big 3**, *Andreessen Horowitz, Morgan Stanley, Blackstone*, can maintain TCRA share liquidity at a high share price for TCRA shareholders and themselves.

To inform the **B7** companies of their extraordinary opportunity, TCRA will leverage access to **B7** by reaching out first to people and nonprofits who have access to Rh Club members, who in turn have access to **executives and board members** of **B7**. Rh Club members will approach each **B7** company and inform them as to how they can make TCRA instantly valuable and save the Rh babies.

The **return** for the new TCRA shareholders will be an immediate funding round post announcements of **$20 billion** cash (**$10 billion** for WIRhE) from selling some TCRA shares in a tender offer, and then receiving the remainder of the **$1 trillion** royalty cash flow over 20 years, salable in lots for present value at any time. The return for philanthropy will be **$500 billion** cash flow over 20 years.

Now to test your grip on reality:
I challenge you to find a flaw in the TCRA ILBOW.
Do you believe the ILBOW will save the Rh babies?
Do you believe B7 will jump on the ILBOW as soon as they understand it?
Do you believe that doubt is safe?